Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain (2016)
- Authors:
- USP affiliated authors: LAURETTI, GABRIELA ROCHA - FMRP ; COELHO, EDUARDO BARBOSA - FMRP ; LANCHOTE, VERA LUCIA - FCFRP
- Unidades: FMRP; FCFRP
- DOI: 10.1111/fcp.12168
- Subjects: ANALGÉSICOS; CITOCROMO P-450; ESTEROIDES
- Keywords: Clearance; CYP2B6; CYP3A; Fraction unbound; Tramadol
- Language: Inglês
- Imprenta:
- Publisher place: West Sussex
- Date published: 2016
- Source:
- Título: Fundamental and Clinical Pharmacology
- ISSN: 0767-3981
- Volume/Número/Paginação/Ano: v. 30, n. 2, p. 153-161, 2016
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
MORAES, Natália V. de et al. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. Fundamental and Clinical Pharmacology, v. 30, n. 2, p. 153-161, 2016Tradução . . Disponível em: https://doi.org/10.1111/fcp.12168. Acesso em: 28 dez. 2025. -
APA
Moraes, N. V. de, Lauretti, G. R., Coelho, E. B., Godoy, A. L. P. C., Neves, D. V., & Lanchote, V. L. (2016). Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. Fundamental and Clinical Pharmacology, 30( 2), 153-161. doi:10.1111/fcp.12168 -
NLM
Moraes NV de, Lauretti GR, Coelho EB, Godoy ALPC, Neves DV, Lanchote VL. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain [Internet]. Fundamental and Clinical Pharmacology. 2016 ; 30( 2): 153-161.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1111/fcp.12168 -
Vancouver
Moraes NV de, Lauretti GR, Coelho EB, Godoy ALPC, Neves DV, Lanchote VL. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain [Internet]. Fundamental and Clinical Pharmacology. 2016 ; 30( 2): 153-161.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1111/fcp.12168 - The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries
- Lercanidipine-fluvastatin interaction: pharmacokinetics stereoselectivity in experimental study
- In vivo activity of CYP2D6 and enantioselective tramadol clearance in patients with neuropathic pain
- Analysis of rocuronium in human plasma by liquid chromatography–tandem mass spectrometry with application in clinical pharmacokinetics
- Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetics
- Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers
- Stereoselective 'alfa'-hydroxylation of metoprolol in hypertensive patients with renal failure
- Stereospecific pharmacodymamics/pharmacokinetics of metoprolol in rats
- Effect of CYP inhibitors on the stereoselective kinetic disposition of metoprolol in rats
- Stereoselective determination of citalopram by liquid chromatography-tandem mass spectrometry in human plasma for pharmacokinetic
Informações sobre o DOI: 10.1111/fcp.12168 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
